Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prelude Therapeutics (Nasdaq: PRLD) reported a narrower third-quarter 2026 net loss of $12.544 million while advancing its oncology clinical programs. Net loss was $0.12 per share, versus $19.725 million, or $0.26 per share, a year earlier. Revenue fell to $5.647 million from $6.500 million. Research and development expenses declined to $14.830 million from $21.708 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $142.7 million at September 30; the company expects funding into the second quarter of 2028. Phase 1 enrollment for breast cancer candidate PRT13722 began in Q4 2026, with initial proof-of-concept data anticipated in the second half of 2027. An October agreement with Lilly supports combination testing. PRT12396 continues Phase 1 enrollment for polycythemia vera and myelofibrosis. Prelude also selected a development candidate for its mCALR-targeted degrader antibody conjugate program.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3 2026 net loss narrowed to $12.544 million, or $0.12 per share, from $19.725 million, or $0.26.
- Moderate point. Forward-looking: it has not happened yet and may not happen.$142.7 million in cash and securities at September 30, 2026 supports expected runway into Q2 2028.
- Moderate pointPRT13722 Phase 1 enrollment began in Q4 2026 following FDA clearance in September 2026.
- Minor pointLilly collaboration signed in October 2026 supplies abemaciclib and imlunestrant for PRT13722 combination testing in HR+/HER2- breast cancer.
- Minor point. Forward-looking: it has not happened yet and may not happen.PRT13722 initial proof-of-concept data anticipated in the second half of 2027.
6 minor points
- Minor pointPRT12396 Phase 1 enrollment continues in patients with polycythemia vera and myelofibrosis.
- Minor pointmCALR-targeted development candidate selected for the wholly owned degrader antibody conjugate program.
- Minor pointQ3 2026 R&D expenses decreased to $14.830 million from $21.708 million a year earlier.
- Minor pointQ3 2026 G&A expenses decreased to $5.082 million from $5.210 million a year earlier.
- Minor pointQ3 2026 operating loss narrowed to $14.265 million from $20.418 million a year earlier.
- Minor pointQ3 2026 other income, net increased to $1.721 million from $0.693 million a year earlier.
Negative
- Major pointVoting common shares outstanding increased to 65,297,977 at September 30, 2026, from 48,225,493 at December 31, 2025.
- Moderate pointQ3 2026 revenue declined to $5.647 million from $6.500 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Incyte's exclusive JAK2V617F program option expires in February 2027, with potential for a 3 month extension.
News Explained
The quarter-end balance sheet lists Prelude Therapeutics with 65,297,977 voting common shares outstanding on
Key Figures
- Revenue
- $5.647 million vs. $6.500 million
- Three months ended September 30, 2026 vs. 2025
- R&D expense
- $14.8 million vs. $21.7 million
- Q3 2026 vs. prior-year period
- G&A expense
- $5.1 million vs. $5.2 million
- Q3 2026 vs. prior-year period
- Net loss
- $12.5 million vs. $19.7 million
- Q3 2026 vs. prior-year period
- Net loss per share
- $0.12 vs. $0.26
- Q3 2026 vs. prior-year period
- Cash and marketable securities
- $142.7 million
- As of September 30, 2026
- Expected cash runway
- Into the second quarter of 2028
- Company expectation
- Initial proof-of-concept data
- Anticipated in the second half of 2027
- PRT13722 Phase 1 study
Previous Earnings Reports
-
Net loss narrowed, cash runway extended into Q2 2028, and pipeline programs advanced.
-
Revenue rose and net loss narrowed year over year, alongside pipeline updates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hr+/her2- medical
polycythemia vera medical
myelofibrosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2nd half of 2027
Entered into a clinical trial collaboration and supply agreement with Lilly to evaluate PRT13722 in combination with Verzenio® and Inluriyo® in patients with HR+/HER2- breast cancer
Continued enrollment in Phase 1 Study of PRT12396, a mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)
Preclinical data from mCALR-targeted degrader antibody conjugate (DAC) lead development candidate accepted for presentation at the American Society of Hematology (ASH) 68th Annual Meeting in December
Current cash runway expected into the second quarter of 2028 with
WILMINGTON, Del., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the third quarter ended September 30, 2026 and provided an update on its R&D pipeline and other corporate developments.
“The first three quarters of 2026 have been a period of strong execution for Prelude,” said Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer. In addition, we advanced our first-in-class mCALR degrader antibody conjugate (DAC) program into preclinical development with the selection of the development candidate, for mCALR+ MPNs, and we look forward to presenting its first preclinical data at ASH in December. With multiple clinical readouts expected over the next 12 to 18 months, we are well positioned to enter 2027 with the momentum to drive future growth of Prelude.”
Program Updates and Upcoming Milestones
Highly selective KAT6A oral degrader program
KAT6 is an emerging and recently validated target in the treatment of HR+ breast cancer. Prelude discovered and is developing highly potent, highly selective and orally bioavailable KAT6A selective degraders. Prelude believes that selectively degrading KAT6A has the potential for improved efficacy, tolerability and combinability with other agents relative to non-selective inhibitors of KAT6A/B.
In September 2026, the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed for the treatment of patients with HR+/HER2- breast cancer. The Company initiated enrollment into the Phase 1 study of PRT13722 in HR+ breast cancer in Q4 2026. The Company anticipates disclosure of initial proof of concept data from this study in the 2nd half of 2027.
Additionally, in October 2026, the Company entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company (“Lilly”) for supply of its CDK4/6 kinase inhibitor, abemaciclib, and its oral estrogen receptor antagonist, imlunestrant. The agreement supports the evaluation of Prelude’s clinical development candidate PRT13722, an oral KAT6A selective degrader, in combinations with abemaciclib and imlunestrant in the existing Phase 1 trial in patients with HR+/HER2- breast cancer.
Updated preclinical data from PRT13722 has been accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium taking place in San Antonio, TX, December 8-11, 2026. Additionally, the Company also has an accepted Trials in Progress poster presentation describing the current Phase 1 study of PRT13722. The abstracts can be found at San Antonio Breast Cancer Symposium® | SABCS 2026.
The Company previously presented preclinical data supporting PRT13722 at the AACR Annual Meeting 2026. The presentation can be found at Publications - Prelude Therapeutics.
Mutant selective JAK2V617F JH2 inhibitor program
JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms (MPNs). The mutation impacts approximately
PRT12396, is currently enrolling patients into a Phase 1 study of PRT12396, Prelude’s lead, mutant-selective JAK2V617F inhibitor in patients with PV and MF. The Company also continues to make progress advancing next generation development candidates with potential best-in-class selectivity profiles.
A Trials in Progress abstract describing the currently enrolling Phase 1 study of PRT12396 has been accepted for poster presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in New Orleans, LA December 12-15, 2026. The abstract can be found on the ASH 2026 website ASH Annual Meeting & Exposition – Hematology.org.
The JAK2V617F inhibitor program is subject to an exclusive option agreement with Incyte announced in November 2025, which is set to expire in February of 2027, with potential for a 3 month extension.
Mutated calreticulin (mCALR) DAC discovery program
Mutant CALR is a neoantigen presented on the cell surface of malignant myeloid cells but not normal cells and is found in approximately 25
The Company presented the preclinical data from the program at the European Hematology Association 2025 Congress in June and the American Society of Hematology (ASH) 67th Annual Meeting in December 2025. The presentations can be found at Publications – Prelude Therapeutics.
Updated preclinical data from the leading development candidate from this program has been accepted for poster presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in New Orleans, LA December 12-15, 2026. The abstract can be found on the ASH 2026 website ASH Annual Meeting & Exposition – Hematology.org.
Degrader payloads for next generation DACs
Prelude is leveraging our expertise in targeted protein degradation to discover and develop novel degrader payloads for use with next generation DACs. We have developed highly potent SMARCA2/4 and CDK9 degrader payloads optimized for efficacy, tolerability and developability when coupled to a wide range of different antibodies. Building on our existing DAC partnership with AbCellera, the Company’s payloads and corresponding payload-linkers are available for licensing to additional partners to expand the reach of this new technology.
We have published preclinical data demonstrating that next generation DACs using Prelude degrader payloads have potential for significantly better in vivo efficacy and tolerability compared to traditional cytotoxic ADCs when tested head-to-head in xenograft models. These data can be found at: Publications – Prelude Therapeutics
Upcoming Investor Conference
The Company will participate in the 9th Annual Evercore Healthcare Conference taking place in Coral Gables, FL. On Wednesday, December 2, 2026 at 7:55 AM ET, Kris Vaddi, Ph.D., Chief Executive Officer, Peggy Scherle, Ph.D., Chief Scientific Officer and Bryant Lim, Chief Financial Officer will participate in a fireside chat.
A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.
Third Quarter 2026 Financial Results
Cash, Cash Equivalents, Restricted cash and Marketable securities:
Cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026 were
Research and Development (R&D) Expenses:
For the three months ended September 30, 2026, R&D expense decreased to
General and Administrative (G&A) Expenses:
For the three months ended September 30, 2026, G&A expenses decreased to
Net Loss:
For the three months ended September 30, 2026, net loss was
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads, including a first-in-class mCALR-targeted DAC. Our mission is to deliver practice-changing cancer medicines. For more information, visit preludetx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, the expected timeline for clinical trial results for Prelude’s product candidates, and the sufficiency of Prelude’s cash runway into the second quarter of 2028. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.
| PRELUDE THERAPEUTICS INCORPORATED | |||||||||
| STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||
| (UNAUDITED) | |||||||||
| Three Months Ended September 30, | |||||||||
| (in thousands, except share and per share data) | 2026 | 2025 | |||||||
| Revenue | $ | 5,647 | $ | 6,500 | |||||
| Operating expenses | |||||||||
| Research and development | 14,830 | 21,708 | |||||||
| General and administrative | 5,082 | 5,210 | |||||||
| Total operating expenses | 19,912 | 26,918 | |||||||
| Loss from operations | (14,265 | ) | (20,418 | ) | |||||
| Other income, net | 1,721 | 693 | |||||||
| Net loss | $ | (12,544 | ) | $ | (19,725 | ) | |||
| Per share information: | |||||||||
| Net loss per share of common stock, basic and diluted | $ | (0.12 | ) | $ | (0.26 | ) | |||
| Weighted average common shares outstanding, basic and diluted | 103,091,149 | 76,132,337 | |||||||
| Comprehensive loss: | |||||||||
| Net loss | $ | (12,544 | ) | $ | (19,725 | ) | |||
| Unrealized (loss) gain on marketable securities, net of tax | (306 | ) | 3 | ||||||
| Comprehensive loss | $ | (12,850 | ) | $ | (19,722 | ) | |||
| PRELUDE THERAPEUTICS INCORPORATED | |||||||||
| BALANCE SHEETS | |||||||||
| (in thousands, except share data) | September 30, 2026 | December 31, 2025 | |||||||
| Assets | (unaudited) | ||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 23,412 | $ | 35,256 | |||||
| Marketable securities | 116,589 | 67,958 | |||||||
| Prepaid expenses and other current assets | 2,426 | 2,478 | |||||||
| Total current assets | 142,427 | 105,692 | |||||||
| Restricted cash | 2,725 | 3,235 | |||||||
| Property and equipment, net | 4,063 | 5,113 | |||||||
| Right-of-use asset | 25,996 | 27,165 | |||||||
| Prepaid expenses and other non-current assets | 274 | 110 | |||||||
| Total assets | $ | 175,485 | $ | 141,315 | |||||
| Liabilities and stockholders’ equity | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 2,971 | $ | 3,983 | |||||
| Accrued expenses and other current liabilities | 8,563 | 12,533 | |||||||
| Deferred revenue | 19,601 | 33,734 | |||||||
| Operating lease liability | 2,796 | 2,744 | |||||||
| Total current liabilities | 33,931 | 52,994 | |||||||
| Deferred revenue, net of current portion | - | 1,798 | |||||||
| Other liabilities | 2,655 | 2,841 | |||||||
| Operating lease liability | 14,763 | 15,045 | |||||||
| Total liabilities | 51,349 | 72,678 | |||||||
| Commitments (Note 8) | |||||||||
| Stockholders’ equity: | |||||||||
| Voting common stock, | 7 | 5 | |||||||
| Non-voting common stock, | 1 | 1 | |||||||
| Additional paid-in capital | 844,572 | 751,684 | |||||||
| Accumulated other comprehensive (loss) income | (533 | ) | 8 | ||||||
| Accumulated deficit | (719,911 | ) | (683,061 | ) | |||||
| Total stockholders’ equity | 124,136 | 68,637 | |||||||
| Total liabilities and stockholders’ equity | $ | 175,485 | $ | 141,315 | |||||
Investor Contact:
Robert A. Doody, Jr.
Senior Vice President, Investor Relations
Prelude Therapeutics Incorporated
484.639.7235
rdoody@preludetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Prelude Therapeutics expect initial PRT13722 clinical data?
Prelude anticipates initial proof-of-concept data in the second half of 2027 from its Phase 1 PRT13722 study. Enrollment began in Q4 2026, and the Lilly collaboration supports testing combinations with abemaciclib and imlunestrant in patients with HR+/HER2- breast cancer.
When does Incyte's option on Prelude's JAK2V617F inhibitor program expire?
Incyte's exclusive option agreement on the JAK2V617F inhibitor program is set to expire in February 2027, with potential for a 3 month extension. The agreement was announced in November 2025.
Why did Prelude Therapeutics' third-quarter 2026 R&D expenses decline?
Lower spending on SMARCA2 clinical trials paused in 2025 and lower employee-related expenses following a workforce reduction in the second half of 2025 primarily drove the decrease, alongside lower stock-based compensation. R&D stock-based compensation was $0.9 million, compared with $1.4 million a year earlier.